Tenderwize
Retour à la recherche

Drug Discount Agreements for Various Active Substances (Open-House)

AOK NordWest - Die Gesundheitskasse·Dortmund, Germany·Deadline Jun 24, 2027 · 300 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Arzneimittel-Rabattverträge ab 01.09.2025 zu diversen Wirkstoffen im Rahmen eines Open-House-Verfahrens

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

Buyer retains right to award exclusive contracts later, which will suspend these open-house agreements. Typically 8-10...

No documented procurement documents analyzed; may contain additional obligations not covered in notice.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Aug 2027
  • Supply of pharmaceutical products (discount agreements) for seven active substances: Budesonide (oral 4mg), Eltrombopag, Fluorouracil (cream), Mebeverine, Nilotinib, Rotigotine, Umeclidinium bromide.
  • Open-house model: any eligible pharmaceutical entrepreneur can join at any time during the contract period.
Afficher le résumé complet

The tender is an open-house procedure for drug discount agreements (Rabattverträge) under §130a Abs. 8 SGB V for seven active substances: Budesonide (oral, 4mg), Eltrombopag, Fluorouracil (cream), Mebeverine, Nilotinib, Rotigotine, and Umeclidinium bromide. The buyer is AOK NordWest. The procedure is not a public procurement under EU directives (per EuGH C-410/14) but published voluntarily. The contract duration is up to 24 months starting 01.09.2025. All eligible pharmaceutical entrepreneurs can join at any time. No estimated value or award criteria are specified. Electronic submission is not allowed; applications are via email. The deadline for submission is 24.06.2027, 23:59 (but continuous accession is possible).

Risques

Buyer retains right to award exclusive contracts later, which will suspend these open-house agreements. Typically 8-10...

No documented procurement documents analyzed; may contain additional obligations not covered in notice.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG for the offered medicinal products, throughout the contract duration.
  • Application via email to [email protected].

Administrative

  • Uniform contract conditions; no individual negotiations.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Dortmund, DEU

Site web

www.aok.de

Identifiant

DE124159739

Activité

Health

Lots (1)

LOT-0001

Drug Discount Agreements for Various Active Substances (Open-House)

All eligible pharmaceutical entrepreneurs can conclude discount agreements for the listed active substances under uniform conditions. The contract runs max. 24 months from 01.09.2025. There is no exclusivity; the buyer may later award exclusive contracts that suspend these agreements.

SuppliesEU fundedElectronic submission

Localisation

Hagen, Germany

Durée

Aug 2025 - Aug 2027

Catégorie

Pharmaceutical products

Date limite

Deadline Jun 24, 2027

Détails de la procédure

Date de publication
17 Jul 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
470057-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30